Pfizer CEO Dr. Albert Bourla and chair of the PhRMA Board of Directors Pharmaceutical Research and Manufacturers of America (PhRMA) Pfizer CEO Dr. Albert Bourla and chair of the PhRMA Board of ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

Pfizer stock has suffered as demand for the company’s top selling coronavirus products declined. The pharma giant has reached an important transition point. Right now, as an investor, you may be ...

Healthcare & Pharmaceuticalscategory· March 11, 2025 Arvinas shares tumble as breast cancer drug with Pfizer shows mixed results Pfizer and Arvinas' experimental treatment failed to delay ...

Influenza causes 140,000 to 710,000 hospitalisations and 12,000 to 52,000 deaths in the US every year, as well as economic losses of around $25 billion a year, according to Pfizer.

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of investors, aiming to add eight ...

Our art critic goes room-by-room through New York’s Gilded Age house museum, reopening after nearly five years. Don’t miss the new upstairs galleries. By Holland Cotter The darkly comic ...